Andrew John Armstrong, MD

Professor of Medicine
Professor in Surgery
Professor in Pharmacology and Cancer Biology
Member of the Duke Cancer Institute
Campus mail Duke Box 103861, Durham, NC 27710
Phone (919) 668-8797
Email address andrew.armstrong@duke.edu

1. Predictors of sensitivity and clinical efficacy of therapies in advanced prostate cancer
2. Novel designs of clinical trials and pharmacodynamic/translational studies in prostate, kidney, bladder cancer
3. Pre-operative models for drug development of novel agents in human testing in prostate cancer
4. Novel therapies and drug development for prostate, renal, bladder, and testicular cancer
5. Design of rational combination therapies in men with metastatic hormone-refractory prostate cancer
6. PI3 kinase/mTOR inhibition in prostate cancer: mechanisms of sensitivity and resistance
7. Developing prognostic models for progression and survival in metastatic prostate cancer
8. Examining surrogate markers of mortality in metastatic prostate cancer
9. Clear cell and non-clear cell renal cell carcinoma: natural history, sensitivity to novel agents including mTOR and VEGF inhibition

In Their Words

Education and Training

  • Fellowship, Division Of Oncology/Hematology, Johns Hopkins University School of Medicine, 2003 - 2006
  • Internship/Residency, General Internal Medicine, University of Pennsylvania, School of Medicine, 2000 - 2003
  • M.Sc., Johns Hopkins University, 2008
  • M.D., University of Virginia School of Medicine, 2000
  • B.S.E., Duke University, 1996

Grants

Publications

Armstrong, Andrew J., Arun A. Azad, Taro Iguchi, Russell Z. Szmulewitz, Daniel P. Petrylak, Jeffrey Holzbeierlein, Arnauld Villers, et al. “Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer.” J Clin Oncol 40, no. 15 (May 20, 2022): 1616–22. https://doi.org/10.1200/JCO.22.00193.

PMID
35420921
Full Text

Zhang, Tian, Julie Kephart, Elizabeth Bronson, Monika Anand, Christine Daly, Ivan Spasojevic, Subha Bakthavatsalam, et al. “Prospective clinical trial of disulfiram plus copper in men with metastatic castration-resistant prostate cancer.” Prostate 82, no. 7 (May 2022): 858–66. https://doi.org/10.1002/pros.24329.

PMID
35286730
Full Text

Gillessen, Silke, Andrew Armstrong, Gert Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Alberto Bossi, et al. “Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.” Eur Urol, April 18, 2022. https://doi.org/10.1016/j.eururo.2022.04.002.

PMID
35450732
Full Text

Turco, Fabio, Andrew Armstrong, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Alberto Bossi, et al. “Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 2022].” Eur Urol, April 16, 2022. https://doi.org/10.1016/j.eururo.2022.04.004.

PMID
35440417
Full Text

Hawkey, Nathan M., Alton O. Sartor, Michael J. Morris, and Andrew J. Armstrong. “Prostate-specific membrane antigen-targeted theranostics: past, present, and future approaches.” Clin Adv Hematol Oncol 20, no. 4 (April 2022): 227–38.

PMID
35389387
Scholars@Duke

Ardolino, L. C., R. Dear, A. J. Armstrong, S. Gillessen, and A. M. Joshua. “Clinical trials for metastatic castrate-resistant prostate cancer-who is looking after the control patients? Questions for the future.” Ann Oncol, March 29, 2022. https://doi.org/10.1016/j.annonc.2022.03.272.

PMID
35364234
Full Text

Brown, Landon C., Susan Halabi, Jason A. Somarelli, Michael Humeniuk, Yuan Wu, Taofik Oyekunle, Lauren Howard, et al. “A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer.” Prostate Cancer Prostatic Dis, March 15, 2022. https://doi.org/10.1038/s41391-022-00524-7.

PMID
35292724
Full Text

Dzimitrowicz, Hannah E., and Andrew J. Armstrong. “Elevating the Patient Voice in Metastatic Hormone-Sensitive Prostate Cancer Clinical Trials.” J Clin Oncol 40, no. 8 (March 10, 2022): 807–10. https://doi.org/10.1200/JCO.21.02504.

PMID
34990219
Full Text

Zhao, Jimmy L., Karim Fizazi, Fred Saad, Kim N. Chi, Mary-Ellen Taplin, Cora N. Sternberg, Andrew J. Armstrong, Johann S. de Bono, William T. Duggan, and Howard I. Scher. “The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial.” Clin Cancer Res 28, no. 5 (March 1, 2022): 860–69. https://doi.org/10.1158/1078-0432.CCR-21-1090.

PMID
34965947
Full Text

Pages